Photo of Scott G. Franzblau

Scott G. Franzblau


Director, Institute for Tuberculosis Research
Albert Schatz Professor, College of Pharmacy - Pharmaceutical Sciences

About

Research Interests:
1) New drug discovery for tuberculosis, non-tuberculous mycobacteria, Lyme Disease and ESKAPE pathogens
2) Antimicrobial assay development
3) Isolation of novel minor bioactive secondary metabolites

Teaching and Supervision

PSCI Ph.D. Thesis Research (PSCI 599), 8/23/2021 – 12/3/2021
Undergrad Res Exp MedChem&Pcog (PMMP 300), 1/14/2019 – 5/3/2019
Spec Project Med Chem &Pcog (PMMP 390), 1/9/2017 – 4/28/2017
Fund of Drug Action III (PHAR 333), 8/22/2016 – 12/2/2016
Fund of Drug Action III (PHAR 333), 8/22/2016 – 12/2/2016
Lab Tech in Pcog I (PMPG 590), 1/11/2016 – 4/29/2016
Fund of Drug Action III (PHAR 333), 8/24/2015 – 12/4/2015
Fund of Drug Action III (PHAR 333), 8/24/2015 – 12/4/2015
Fund of Drug Action III (PHAR 333), 8/25/2014 – 12/5/2014

Selected Grants

Design, Syntheses and Studies of Novel Antituberculosis Agents, University of Notre Dame., 9/1/2021 - 8/31/2022, Obligated Amount: $92899; Anticipated Amount: $92899

Provide heat inactivated cell suspensions of four mycobacterial strains to EpicGenetics, EpicGenetics., 8/1/2021 - 1/31/2022, Obligated Amount: $3980; Anticipated Amount: $3980

★ Modulation of Protein production and Degradation as an integrated approach to rapid sterilization of Drug sensitive and resistant Mtb, Global Alliance for TB Drug Development., 4/1/2019 - 3/31/2022, Obligated Amount: $5573136; Anticipated Amount: $5573136

★ “Targeting Protein Degradation ClpC1 ATPase”, National Institutes of Health., 1/4/2019 - 3/31/2024, Obligated Amount: $3834174; No Anticipated Amount Set

A new paradigm for the creation and mining of microbial libraries for drug discovery, National Institutes of Health (National Institute of General Medical Sciences)., 8/10/2018 - 7/31/2022, Obligated Amount: $2069671; Anticipated Amount: $2069671

Enhancing basic and translational TB research in northern Vietnam, National Institutes of Health., 7/1/2017 - 6/30/2022, Obligated Amount: $52396; No Anticipated Amount Set

A Novel Antibiotic Strategy Exploiting Metabolite Self-Toxicity, Chicago Biomedical Consortium., 3/1/2017 - 2/28/2019, Obligated Amount: $100000; Anticipated Amount: $100000

High-Throughput Screening and Validation of Inhibitors Against M. Tuberculosis Class II FBPase, Chicago Biomedical Consortium., 10/1/2016 - 3/31/2018, No Obligated Amount Set; No Anticipated Amount Set

★ In Vitro Testing of Candidate Anti-Tubercular Compounds, Global Alliance for TB Drug Development., 10/1/2005 - 4/30/2023, Obligated Amount: $10497860; Anticipated Amount: $10497860

Selected Publications

Zhou, B, Achanta, PS, Shetye, G, Chen, SN, Lee, H, Jin, YY, Cheng, J, Lee, MJ, Suh, JW, Cho, S, Franzblau, SG, Pauli, GF, McAlpine, JB. (2021). Rufomycins or Ilamycins: Naming Clarifications and Definitive Structural Assignments. Journal of Natural Products, 84, (10), 2644-2663. doi:10.1021/acs.jnatprod.1c00198.

Park, CR, Paik, S, Kim, YJ, Kim, JK, Jeon, SM, Lee, SH, Whang, J, Cheng, J, Suh, JW, Cao, J, Shetye, G, Chen, SN, McAlpine, J, Pauli, GF, Franzblau, S, Cho, S, Jo, EK. (2021). Rufomycin Exhibits Dual Effects Against Mycobacterium abscessus Infection by Inducing Host Defense and Antimicrobial Activities. Frontiers in Microbiology, 12. doi:10.3389/fmicb.2021.695024.

Shetye, GS, Choi, KB, Kim, CY, Franzblau, SG, Cho, S. (2021). In vitro profiling of antitubercular compounds by rapid, efficient, and nondestructive assays using autoluminescent mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 65, (8). doi:10.1128/AAC.00282-21.

Nandikolla, A, Srinivasarao, S, Khetmalis, YM, Kumar, BK, Murugesan, S, Shetye, G, Ma, R, Franzblau, SG, Sekhar, KVGC. (2021). Design, synthesis and biological evaluation of novel 1,2,3-triazole analogues of Imidazo-[1,2-a]-pyridine-3-carboxamide against Mycobacterium tuberculosis. Toxicology in Vitro, 74. doi:10.1016/j.tiv.2021.105137.

Primi, MC, Tavares, MT, Klein, LL, Izard, T, Sant’anna, CMR, Franzblau, SG, Ferreira, EI. (2021). Design of novel phosphopantetheine adenylyltransferase inhibitors: A potential new approach to tackle mycobacterium tuberculosis. Current Topics in Medicinal Chemistry, 21, (13), 1186-1197. doi:10.2174/1568026621666210728094804.

Ganesan, MS, Raja, KK, Murugesan, S, Karankumar, B, Faheem, F, Thirunavukkarasu, S, Shetye, G, Ma, R, Franzblau, SG, Wan, B, Rajagopal, G. (2021). Quinoline-Proline, Triazole Hybrids: Design, Synthesis, Antituberculosis, Molecular Docking, and ADMET Studies. Journal of Heterocyclic Chemistry, 58, (4), 952-968. doi:10.1002/jhet.4229.

Thompson, AM, O’Connor, PD, Yardley, V, Maes, L, Launay, D, Braillard, S, Chatelain, E, Wan, B, Franzblau, SG, Ma, Z, Cooper, CB, Denny, WA. (2021). Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced Solubility. ACS Medicinal Chemistry Letters, 12, (2), 275-281. doi:10.1021/acsmedchemlett.0c00649.

Thompson, AM, O’Connor, PD, Marshall, AJ, Yardley, V, Maes, L, Gupta, S, Launay, D, Braillard, S, Chatelain, E, Wan, B, Franzblau, SG, Ma, Z, Cooper, CB, Denny, WA. (2021). Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal. European Journal of Medicinal Chemistry, 209. doi:10.1016/j.ejmech.2020.112914.

Liu, R, Markley, L, Miller, PA, Franzblau, S, Shetye, G, Ma, R, Savková, K, Mikušová, K, Lee, BS, Pethe, K, Moraski, GC, Miller, MJ. (2021). Hydride-induced Meisenheimer complex formation reflects activity of nitro aromatic anti-tuberculosis compounds. RSC Medicinal Chemistry, 12, (1), 62-72. doi:10.1039/d0md00390e.

Education

Degrees:
B.S, Rutgers University, United States, 1976
MS, University of Arizona, United States, 1978
PhD, University of Arizona, United States, 1982

Postgraduate Training:
Postgraduate, Kurume University, Japan, 1984

Selected Presentations

Wolf, Nina M, Lee, Hyun, Nam, Joowon, Hong, Jeongpyo, Duc, Nguyen Minh, Ho, Ngo Anh, Lee, Hanki, Suh, Joo-Won, Pauli, Guido F, Franzblau, Scott G, Cho, Sanghyun, Abad-Zapatero, Celerino. (2019 July 20). Structures of ClpC1-NTD with potent anti-TB cyclic peptides Rufomycin and Ecumicin: implications for the mechanism of action and design of therapeutic agents. doi:10.1107/s0108767319099409.